Why Relmada Therapeutics, Inc.’s (RLMD) Stock Is Down 5.77%
As of Friday, November 13, Relmada Therapeutics, Inc.’s RLMD share price has dipped by 5.77%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Michael Rose
Jenna Brashear
Rosalio Madrigal
Jenna Brashear
| Share Statistics | RLMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $449.2 | $447.9 | 37% |
|
| Shares Out (Mil) | 112.4 | 46.7 | 64% |
|
| Institutional Ownership | 95.9% | 80.9% | 68% |
|
| Float (Mil) | 82.6 | 46.8 | 57% |
|
| Beta | 0.57 | 0.74 | 32% |
|
| Avg Daily Volume (000s) | 1,632 | 342 | 76% |
|
| Price Change (52-week) |
7.7% | 54.7% | 57% |
|
| Growth | RLMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | 0.7% | (1.6%) | 41% |
|
| EPS (5yr) | 17.5% | 15.0% | 64 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 65.9% | (15.1%) | 96% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RLMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $303 | na |
|
| Net Income (TTM) (Mil) | ($66) | ($10) | 14% |
|
| EPS (TTM) | ($0.706) | ($0.600) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($52) | ($7) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $1 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $242 | $408 | 28% |
|
| Valuation | RLMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.31 | 2.19 | 60% |
|
| P/E | na | 22.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | RLMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.9% | na |
|
| ROA | (59.7%) | (22.7%) | 10% |
|
| ROE | (64.7%) | (25.0%) | 13% |
|
| Liabilities to Assets | 5.6% | 31.8% | 3% |
|
| F-Score | 3 | 3 | 18% |
|
Relmada Therapeutics, Inc. did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors